MCID: CSH001
MIFTS: 65

Cushing's Syndrome malady

Categories: Rare diseases, Endocrine diseases, Genetic diseases, Reproductive diseases

Aliases & Classifications for Cushing's Syndrome

Aliases & Descriptions for Cushing's Syndrome:

Name: Cushing's Syndrome 12 50 51 41 14
Cushing Syndrome 12 50 52 42 69
Hypercortisolism 50 51 29 52
Cushing's Disease 29 14
Adrenal Hyperfunction Resulting from Pituitary Acth Excess 50
Ectopic Adrenocorticotropic Hormone Syndrome 50
Nodular Primary Adrenocortical Dysplasia 50
Adrenal Gland Hyperfunction 69
Adrenal Cushing's Syndrome 69
Adrenal Cortical Adenoma 69
Suprarenogenic Syndrome 12
Adrenal Cortex Adenoma 50
Acth Syndrome, Ectopic 69
Pituitary Basophilism 12
Ectopic Acth Syndrome 50
Acth Syndrome Ectopic 52
Hyperadrenocorticism 50

Classifications:



External Ids:

Disease Ontology 12 DOID:12252
ICD10 33 E24 E24.9 E24.3
ICD9CM 35 255.0
MeSH 42 D003480
NCIt 47 C2969
UMLS 69 C0010481

Summaries for Cushing's Syndrome

NINDS : 51 Cushing's syndrome, also called , is a rare endocrine disorder caused by chronic exposure of the body's tissues to excess levels of cortisol - a hormone naturally produced by the adrenal gland. Exposure to too much cortisol can occur from long-term use of synthetic glucocorticoid hormones to treat inflammatory illnesses. Pituitary adenomas (benign tumors of the pituitary gland) that secrete increased amounts of ACTH ( a substance that controls the release of cortisol) can also spur overproduction of cortisol. Tumors of the adrenal gland and ectopic ACTH syndrome (a condition in which ACTH is produced by various types of potentially malignant tumors that occur in different parts of the body) can cause similar problems with cortisol balance. Common symptoms of Cushing's syndrome include upper body obesity, severe fatigue and muscle weakness, high blood pressure, backache, elevated blood sugar, easy bruising, and bluish-red stretch marks on the skin. In women, there may be increased growth of facial and body hair, and menstrual periods may become irregular or stop completely. Neurological symptoms include difficulties with memory and neuromuscular disorders.

MalaCards based summary : Cushing's Syndrome, also known as cushing syndrome, is related to pheochromocytoma and ectopic cushing syndrome, and has symptoms including fatigue, reduced consciousness/confusion and abdominal pain. An important gene associated with Cushing's Syndrome is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Epinephrine and Mifepristone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, adrenal gland and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and behavior/neurological

NIH Rare Diseases : 50 cushing's syndrome is an endocrine disorder caused by prolonged exposure of the body's tissues to high levels of cortisol (a hormone produced by the adrenal gland). it most commonly affects adults between age 20 and 50 years. signs and symptoms of cushing's syndrome include upper body obesity, fatigue, muscle weakness, high blood pressure, backache, high blood sugar, easy bruising and bluish-red stretch marks on the skin. affected women may also experience irregular menstrual periods and increased growth of body and facial hair. this condition may be caused by a variety of factors including long-term use of corticosteroid medications, tumors in the pituitary gland or adrenal adenomas.treatment depends on the underlying cause, but may include decreasing the dosage of corticosteroids or surgery to remove tumors. last updated: 11/28/2014

MedlinePlus : 41 cushing's syndrome is a hormonal disorder. the cause is long-term exposure to too much cortisol, a hormone that your adrenal gland makes. sometimes, taking synthetic hormone medicine to treat an inflammatory disease leads to cushing's. some kinds of tumors produce a hormone that can cause your body to make too much cortisol. cushing's syndrome is rare. some symptoms are upper body obesity thin arms and legs severe fatigue and muscle weakness high blood pressure high blood sugar easy bruising lab tests can show if you have it and find the cause. your treatment will depend on why you have too much cortisol. if it is because you have been taking synthetic hormones, a lower dose may control your symptoms. if the cause is a tumor, surgery and other therapies may be needed. nih: national institute of diabetes and digestive and kidney diseases

Disease Ontology : 12 An adrenal gland hyperfunction that is caused by overactivity of the adrenal cortex caused by a tumor of the pituitary gland.

Wikipedia : 71 Cushing\'s syndrome is a collection of signs and symptoms due to prolonged exposure to cortisol. Signs... more...

Related Diseases for Cushing's Syndrome

Diseases in the Cushing's Syndrome family:

Cushing Syndrome, Familial Cushing Syndrome Due to Macronodular Adrenal Hyperplasia

Diseases related to Cushing's Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)
id Related Disease Score Top Affiliating Genes
1 pheochromocytoma 29.3 CHGA CRH POMC SST
2 ectopic cushing syndrome 12.3
3 cushing syndrome due to macronodular adrenal hyperplasia 11.9
4 pituitary adenoma, acth-secreting 11.8
5 cushing syndrome, familial 11.7
6 acth-independent macronodular adrenal hyperplasia 11.6
7 pigmented nodular adrenocortical disease, primary, 4 11.6
8 pigmented nodular adrenocortical disease, primary, 3 11.5
9 pigmented nodular adrenocortical disease, primary, 1 11.5
10 pigmented nodular adrenocortical disease, primary, 2 11.4
11 acth-independent macronodular adrenal hyperplasia 2 11.4
12 glucocorticoid resistance 10.9
13 mccune-albright syndrome, somatic, mosaic 10.9
14 primary pigmented nodular adrenocortical disease 10.5
15 nelson syndrome 10.5
16 burning mouth syndrome type 3 10.3 POMC SST
17 renal hypoplasia, bilateral 10.3 POMC SST
18 water-clear cell adenoma 10.3 POMC SST
19 vaginal adenoma 10.3 POMC SST
20 african histoplasmosis 10.3 POMC SST
21 early-onset parkinson disease 10.2 CRH POMC SST
22 keratosis 10.2 CRH NR3C1 POMC
23 secondary syphilis 10.2 CHGA SST
24 brain edema 10.2 CHGA SST
25 immune system organ benign neoplasm 10.2 CRH POMC SST
26 hereditary multiple exostoses 10.2 CRH NR3C1 POMC
27 cleft lip palate-tetraphocomelia 10.2 CYP21A2 POMC
28 grin2a-related speech disorders and epilepsy 10.2 GH1 GNAS
29 uterine ligament cancer 10.2 GNAS PRKAR1A SST
30 lichen disease 10.2 CRH NR3C1 POMC
31 endocrine organ benign neoplasm 10.2 CRH POMC SST
32 distal monosomy 14q 10.2 CYP21A2 POMC
33 extragonadal nonseminomatous germ cell tumor 10.2 POMC SST
34 macrocephaly, benign familial 10.2 GH1 POMC
35 ataxia, spastic, 5, autosomal recessive 10.2 MC2R POMC
36 cerebral hemisphere lipoma 10.2 GH1 SST
37 mitochondrial complex ii deficiency 10.2 CHGA POMC SST
38 congenital tricuspid stenosis 10.2 GH1 POMC
39 lymph node cancer 10.2 CRH NR3C1
40 intermittent squint 10.2 CRH GH1 POMC
41 bone dysplasia azouz type 10.2 CHGA CRH SST
42 eccrine papillary adenocarcinoma 10.2 CHGA POMC SST
43 non-syndromic x-linked intellectual disability 10.1 CHGA POMC SST
44 hypogonadism cardiomyopathy 10.1 CRH GH1 POMC
45 malignant otitis externa 10.1 CRH CYP21A2 POMC
46 dyt1 early-onset isolated dystonia 10.1 CYP21A2 POMC
47 pemphigus vegetans 10.1 GH1 SST
48 nonparalytic poliomyelitis 10.1 CRH NR3C1 POMC SST
49 loeffler endocarditis 10.1 CRH CYP21A2 POMC
50 capillary lymphangioma 10.1 CRH GH1 POMC

Graphical network of the top 20 diseases related to Cushing's Syndrome:



Diseases related to Cushing's Syndrome

Symptoms & Phenotypes for Cushing's Syndrome

Human phenotypes related to Cushing's Syndrome:

32 (show all 39)
id Description HPO Frequency HPO Source Accession
1 fatigue 32 HP:0012378
2 reduced consciousness/confusion 32 HP:0004372
3 abdominal pain 32 HP:0002027
4 muscle weakness 32 HP:0001324
5 depression 32 HP:0000716
6 diabetes mellitus 32 HP:0000819
7 hypertension 32 HP:0000822
8 sleep disturbance 32 HP:0002360
9 cataract 32 HP:0000518
10 aseptic necrosis 32 HP:0010885
11 hypokalemia 32 HP:0002900
12 myopathy 32 HP:0003198
13 osteoporosis 32 HP:0000939
14 irritability 32 HP:0000737
15 thin skin 32 HP:0000963
16 generalized hirsutism 32 HP:0002230
17 acne 32 HP:0001061
18 anxiety 32 HP:0000739
19 secondary amenorrhea 32 HP:0000869
20 growth delay 32 HP:0001510
21 psychosis 32 HP:0000709
22 striae distensae 32 HP:0001065
23 decreased fertility 32 HP:0000144
24 round face 32 HP:0000311
25 purpura 32 HP:0000979
26 nephrolithiasis 32 HP:0000787
27 recurrent fractures 32 HP:0002757
28 hyponatremia 32 HP:0002902
29 hypercholesterolemia 32 HP:0003124
30 hypercalcemia 32 HP:0003072
31 bruising susceptibility 32 HP:0000978
32 abnormality of the gastric mucosa 32 HP:0004295
33 erectile abnormalities 32 HP:0100639
34 dilated cardiomyopathy 32 HP:0001644
35 truncal obesity 32 HP:0001956
36 abnormal subcutaneous fat tissue distribution 32 HP:0007552
37 increased circulating cortisol level 32 HP:0003118
38 neoplasm of the adrenal gland 32 HP:0100631
39 telangiectasia of the skin 32 HP:0100585

UMLS symptoms related to Cushing's Syndrome:


cushingoid facies, agitation

GenomeRNAi Phenotypes related to Cushing's Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.72 HSD11B2 POMC GH1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.72 POMC
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.72 GH1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.72 HSD11B2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.72 POMC
6 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.72 GH1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.72 GH1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.72 HSD11B2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.72 GH1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.72 HSD11B2 GH1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.72 GH1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.72 POMC
13 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.72 POMC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.72 HSD11B2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.72 HSD11B2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.72 GH1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.72 HSD11B2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.72 HSD11B2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.72 HSD11B2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.72 POMC
21 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.72 POMC
22 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.72 GH1

MGI Mouse Phenotypes related to Cushing's Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.16 POMC PRKAR1A SST CRH GNAS HSD11B1
2 endocrine/exocrine gland MP:0005379 10.1 CHGA CRH GIPR GNAS HSD11B1 MC2R
3 homeostasis/metabolism MP:0005376 10.1 CHGA CRH GIPR GNAS HSD11B1 HSD11B2
4 cardiovascular system MP:0005385 10.09 CHGA GNAS HSD11B1 HSD11B2 MC2R NR3C1
5 adipose tissue MP:0005375 10.08 CRH GNAS HSD11B1 MC2R NR3C1 POMC
6 growth/size/body region MP:0005378 10.07 NR3C1 POMC PRKACA PRKAR1A SST CHGA
7 nervous system MP:0003631 9.81 CRH GNAS HSD11B1 MC2R NR3C1 PDE11A
8 liver/biliary system MP:0005370 9.73 CRH GNAS HSD11B1 NR3C1 POMC PRKAR1A
9 no phenotypic analysis MP:0003012 9.43 CRH GNAS HSD11B2 NR3C1 POMC SST
10 renal/urinary system MP:0005367 9.17 CHGA CRH GNAS HSD11B2 NR3C1 POMC

Drugs & Therapeutics for Cushing's Syndrome

Drugs for Cushing's Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2 51-43-4 5816
2
Mifepristone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84371-65-3 55245
3
Somatostatin Approved Phase 4,Phase 2 38916-34-6, 51110-01-1 53481605
4 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
5 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
6 Hormones Phase 4,Phase 2,Phase 3,Phase 1
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
8 Epinephryl borate Phase 4,Phase 3,Phase 2
9 Racepinephrine Phase 4,Phase 3,Phase 2
10 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Phase 1
12 Contraceptives, Postcoital Phase 4,Phase 3,Phase 2,Phase 1
13 Luteolytic Agents Phase 4,Phase 3,Phase 2,Phase 1
14
Lactitol Phase 4 585-86-4 3871
15
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
16
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
17
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
18
Metyrapone Approved Phase 3 54-36-4 4174
19
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
20 Anesthetics Phase 2, Phase 3
21 Hypoglycemic Agents Phase 2, Phase 3
22 beta-endorphin Phase 3,Phase 2
23 Mydriatics Phase 2, Phase 3
24 Adrenergic Agents Phase 2, Phase 3
25 Adrenergic Agonists Phase 2, Phase 3
26 Adrenergic alpha-Agonists Phase 2, Phase 3
27 Adrenergic beta-Agonists Phase 2, Phase 3
28 Neurotransmitter Agents Phase 2, Phase 3
29 Adrenocorticotropic Hormone Phase 3,Phase 2
30 Cortisol succinate Phase 3,Phase 2,Phase 1
31 Androgens Phase 2, Phase 3
32 Peripheral Nervous System Agents Phase 3,Phase 2
33 Vasoconstrictor Agents Phase 2, Phase 3
34 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2,Phase 1
35 Hydrocortisone acetate Phase 3,Phase 2,Phase 1
36 Anti-Asthmatic Agents Phase 2, Phase 3
37 Anti-Inflammatory Agents Phase 3,Phase 2
38 Interleukin 1 Receptor Antagonist Protein Phase 3
39 Respiratory System Agents Phase 2, Phase 3
40 Melanocyte-Stimulating Hormones Phase 3,Phase 2
41 Antirheumatic Agents Phase 3
42 Autonomic Agents Phase 3,Phase 2
43 Bronchodilator Agents Phase 2, Phase 3
44 Dexamethasone acetate Phase 3 1177-87-3
45
protease inhibitors Phase 3
46 Gastrointestinal Agents Phase 3,Phase 2
47 HIV Protease Inhibitors Phase 3
48 Dexamethasone 21-phosphate Phase 3
49 Antiemetics Phase 3,Phase 2
50 Antimetabolites Phase 3

Interventional clinical trials:

(show top 50) (show all 75)
id Name Status NCT ID Phase
1 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism Completed NCT01990560 Phase 4
2 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
3 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
4 Prevention of Metabolic Complications of Glucocorticoid Excess Unknown status NCT01319994 Phase 2, Phase 3
5 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3
6 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3
7 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3
8 Effects of IL-1 Beta on the HPA-axis in Obese Persons Completed NCT02227420 Phase 3
9 Treatment for Endogenous Cushing's Syndrome Recruiting NCT01838551 Phase 3
10 Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome Recruiting NCT02297945 Phase 3
11 Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? Recruiting NCT01504555 Phase 3
12 Dynamic Hormone Diagnostics in Endocrine Disease Not yet recruiting NCT02934399 Phase 2, Phase 3
13 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3
14 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2
15 SOM230 Ectopic ACTH-producing Tumors Recruiting NCT02780882 Phase 2
16 Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome Recruiting NCT02019706 Phase 2
17 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Recruiting NCT02468193 Phase 2
18 New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome Recruiting NCT00001849 Phase 1, Phase 2
19 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Recruiting NCT02804750 Phase 2
20 A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome Recruiting NCT03053271 Phase 2
21 Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus Recruiting NCT03052400 Phase 2
22 Mifepristone for Metabolic Syndrome Recruiting NCT01419535 Phase 1, Phase 2
23 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2
24 Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism Active, not recruiting NCT02001051 Phase 2
25 Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs Not yet recruiting NCT02611258 Phase 2
26 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Not yet recruiting NCT03111810 Phase 2
27 Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Terminated NCT00422201 Phase 2
28 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2
29 Pasireotide Therapy in Patients With Nelson's Syndrome Terminated NCT01617733 Phase 2
30 Insulin Sensitivity and Substrate Metabolism in Patients With Cushing's Syndrome Unknown status NCT00682084
31 Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome Unknown status NCT00004343
32 Study of Depression, Peptides, and Steroids in Cushing's Syndrome Unknown status NCT00004334
33 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335
34 Long Term Post Operative Follow-Up of Cushing Syndrome Completed NCT00029952
35 Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome Completed NCT00001453
36 Hippocampal Complex Volume and Memory Dysfunction in Cushing's Syndrome Completed NCT00004326
37 Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome Completed NCT01688349
38 In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man Completed NCT02889224
39 Study of Cushing's Syndrome Not Related to ACTH Production Completed NCT00006278
40 Cognition, Steroids, and Imaging in Cushings Disease Completed NCT00081341
41 Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency Completed NCT00001180
42 The Factors Associated With the Recurrence in Patients With Cushing Disease Completed NCT02233335
43 Efficacy and Safety of Posterior Retroperitoneoscopic Adrenalectomy: A Comparative Study Completed NCT02618694
44 Heart Disease Risk Factors in Major Depression Completed NCT00001969
45 Metabolic Effects of Acute Cortisol Withdrawal in Adrenal Failure Completed NCT00442390
46 To Study Polycystic Ovary Syndrome in Taiwanese Women Completed NCT01256944
47 Serum Calcium to Phosphorous Ratio (Ca/P) as a Simple, Inexpensive Screening Tool in the Diagnosis of Primary Hyperparathyroidism Completed NCT03027349
48 Adolescence, Puberty, and Emotion Regulation Completed NCT00016731
49 Dynamics of Leptin and Endocrine Function Completed NCT00001543
50 Study of Adrenal Gland Tumors Recruiting NCT00005927

Search NIH Clinical Center for Cushing's Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: cushing syndrome

Genetic Tests for Cushing's Syndrome

Genetic tests related to Cushing's Syndrome:

id Genetic test Affiliating Genes
1 Cushing's Syndrome 29
2 Hypercortisolism 29

Anatomical Context for Cushing's Syndrome

MalaCards organs/tissues related to Cushing's Syndrome:

39
Pituitary, Adrenal Gland, Skin, Testes, Cortex, Adrenal Cortex, Bone

Publications for Cushing's Syndrome

Articles related to Cushing's Syndrome:

(show top 50) (show all 1037)
id Title Authors Year
1
Which type 2 diabetes mellitus patients should be screened for subclinical Cushing's syndrome? ( 28500825 )
2017
2
Glucose metabolism abnormalities in Cushing's syndrome: from molecular basis to clinical management. ( 28368467 )
2017
3
Case of diabetic ketoacidosis as an initial presentation of Cushing's syndrome. ( 28458895 )
2017
4
Exogenous Cushing's syndrome due to a Chinese herbalist's prescription of ointment containing dexamethasone. ( 28432185 )
2017
5
Extended low-dose dexamethasone suppression test for diagnosis of atypical Cushing's syndrome in dogs. ( 28371654 )
2017
6
Diagnosis and Differential Diagnosis of Cushing's Syndrome. ( 28402781 )
2017
7
Cushing's syndrome managed by endoscopic ultrasound-guided radiofrequency ablation of adrenal gland adenoma. ( 28068682 )
2017
8
Characteristics and Mortality of Pneumocystis Pneumonia in Patients With Cushing's Syndrome: A Plea for Timely Initiation of Chemoprophylaxis. ( 28480275 )
2017
9
Increased prevalence of obstructive sleep apnea in patients with Cushing's syndrome compared with weight- and age-matched controls. ( 27932409 )
2017
10
Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management. ( 28393326 )
2017
11
Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry. ( 28325824 )
2017
12
Ritonavir and Topical Ocular Corticosteroid Induced Cushing's Syndrome in an Adolescent with HIV-1 Infection. ( 28060049 )
2017
13
Acute mesenteric ischemia and hepatic infarction after treatment of ectopic Cushing's syndrome. ( 28480039 )
2017
14
Bronchopulmonary carcinoid with a single lymph node metastasis causing ectopic Cushing's syndrome. ( 28449502 )
2017
15
Cushing's syndrome: a practical approach to diagnosis and differential diagnoses. ( 28069628 )
2017
16
Portal Vein Thrombosis in the Setting of Newly Diagnosed Cushing's Syndrome. ( 28491882 )
2017
17
Cushing's Syndrome and Treatment-Resistant Depression. ( 28515565 )
2017
18
Cushing's syndrome in infancy due to ectopic ACTH secretion by a sacro-coccygeal teratoma. ( 28328532 )
2017
19
Affective alterations in patients with Cushing's syndrome in remission are associated with decreased BDNF and cortisone levels. ( 27932530 )
2017
20
Clobetasol, Acitretin, and Cushing's Syndrome. ( 28297151 )
2017
21
Body composition in pituitary, adrenal and iatrogenic Cushing's syndrome and effects of DHEAS levels. ( 27696526 )
2017
22
Cushing's Syndrome, Cortisol, and Cognitive Competency: A Case Report. ( 28512418 )
2017
23
Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. ( 28377460 )
2017
24
Growth hormone deficiency in treated acromegaly and active Cushing's syndrome. ( 28477735 )
2017
25
Zinc alpha-2 glycoprotein is overproduced in Cushing's syndrome. ( 28440767 )
2017
26
White matter involvement on DTI-MRI in Cushing's syndrome relates to mood disturbances and processing speed: a case-control study. ( 28332051 )
2017
27
A Rare Case of Subclinical Primary Aldosteronism and Subclinical Cushing's Syndrome without Cardiovascular Complications. ( 27050894 )
2016
28
Cushing's Syndrome And Steroid Dementia. ( 27515536 )
2016
29
E2F1-mediated human POMC expression in ectopic Cushing's syndrome. ( 27935805 )
2016
30
Vascular health in patients in remission of Cushing's syndrome is comparable to that in BMI-matched controls. ( 27552540 )
2016
31
Cushing's syndrome due to ectopic ACTH secretion. ( 27387249 )
2016
32
Brain metabolite abnormalities in ventromedial prefrontal cortex are related to duration of hypercortisolism and anxiety in patients with Cushing's syndrome. ( 27103571 )
2016
33
Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome. ( 26989527 )
2016
34
Cushing's syndrome. ( 27551694 )
2016
35
Bilateral testicular tumors resulting in recurrent Cushing's syndrome after bilateral adrenalectomy". ( 27901643 )
2016
36
MECHANISMS IN ENDOCRINOLOGY: Tissue-Specific Activation of Cortisol in Cushing's Syndrome. ( 26957494 )
2016
37
Role of "old" pharmacological agents in the treatment of Cushing's syndrome. ( 27086313 )
2016
38
Adrenalectomy for Cushing's syndrome: do's and don'ts. ( 27928434 )
2016
39
Complications of Cushing's syndrome: state of the art. ( 27177728 )
2016
40
Cushing's Syndrome From Pituitary Microadenoma and Pulmonary Nodules. ( 26906124 )
2016
41
Markers of atherosclerosis in patients with Cushing's syndrome: a meta-analysis of literature studies. ( 27763781 )
2016
42
Incompatibility between fasting and postprandial plasma glucose in patients with Cushing's syndrome. ( 27498594 )
2016
43
Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome. ( 27766686 )
2016
44
Skin manifestations of Cushing's syndrome. ( 27943005 )
2016
45
Ketoconazole and endogenous Cushing's syndrome. Effective but tricky to use. ( 27152395 )
2016
46
Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies. ( 27600150 )
2016
47
Cushing's Syndrome: Screening and Diagnosis. ( 27160717 )
2016
48
A probabilistic model for Cushing's syndrome screening in at-risk populations: a prospective multicenter study. ( 27490917 )
2016
49
Cushing's Syndrome: Where and How to Find It. ( 27211887 )
2016
50
Evaluation of an automated chemiluminescent immunoassay for salivary cortisol measurement. Utility in the diagnosis of Cushing's syndrome. ( 27580182 )
2016

Variations for Cushing's Syndrome

ClinVar genetic disease variations for Cushing's Syndrome:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
2 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
3 GNAS NM_000516.5(GNAS): c.601C> A (p.Arg201Ser) single nucleotide variant Pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420

Expression for Cushing's Syndrome

Search GEO for disease gene expression data for Cushing's Syndrome.

Pathways for Cushing's Syndrome

Pathways related to Cushing's Syndrome according to GeneCards Suite gene sharing:

(show all 23)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.33 CRH GH1 GIPR GNAS MC2R NR3C1
2
Show member pathways
12.56 CRH GH1 GNAS POMC PRKACA PRKAR1A
3
Show member pathways
12.38 GNAS POMC PRKACA PRKAR1A
4
Show member pathways
12.36 CRH GNAS PRKACA PRKAR1A
5
Show member pathways
12.22 CYP21A2 GNAS MC2R PRKACA
6
Show member pathways
12.08 GIPR GNAS MC2R PRKACA
7
Show member pathways
11.97 GNAS PRKACA PRKAR1A
8 11.95 NR3C1 PRKACA PRKAR1A SST
9
Show member pathways
11.86 GNAS PRKACA PRKAR1A
10
Show member pathways
11.69 GNAS PRKACA PRKAR1A
11 11.67 GNAS PRKACA PRKAR1A
12 11.63 NR3C1 POMC PRKACA
13 11.57 GH1 GNAS PRKACA PRKAR1A
14
Show member pathways
11.48 CYP21A2 HSD11B1 HSD11B2
15 11.43 CRH CYP21A2 GNAS POMC
16 11.26 CRH GIPR GNAS MC2R PDE11A POMC
17
Show member pathways
11.2 CYP21A2 HSD11B1 HSD11B2 POMC
18 11.19 POMC PRKACA PRKAR1A
19 11.14 GNAS PRKACA PRKAR1A
20 10.97 GNAS PRKACA
21 10.88 GNAS NR3C1
22 10.79 GNAS PRKACA PRKAR1A
23 10.36 CRH POMC

GO Terms for Cushing's Syndrome

Cellular components related to Cushing's Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane raft GO:0044853 8.96 PRKACA PRKAR1A
2 cAMP-dependent protein kinase complex GO:0005952 8.62 PRKACA PRKAR1A

Biological processes related to Cushing's Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.71 CRH GNAS HSD11B2 SST
2 steroid metabolic process GO:0008202 9.61 CRH CYP21A2 HSD11B1
3 female pregnancy GO:0007565 9.54 CRH GNAS HSD11B2
4 activation of protein kinase A activity GO:0034199 9.46 PRKACA PRKAR1A
5 cellular response to glucagon stimulus GO:0071377 9.43 GNAS PRKACA PRKAR1A
6 renal water homeostasis GO:0003091 9.33 GNAS PRKACA PRKAR1A
7 hormone-mediated apoptotic signaling pathway GO:0008628 9.32 CRH SST
8 positive regulation of cAMP biosynthetic process GO:0030819 9.26 CRH GIPR GNAS MC2R
9 glucocorticoid biosynthetic process GO:0006704 8.92 CRH CYP21A2 HSD11B1 HSD11B2

Molecular functions related to Cushing's Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 9.33 CYP21A2 HSD11B2 NR3C1
2 cAMP binding GO:0030552 9.32 PDE11A PRKAR1A
3 corticotropin-releasing hormone receptor 1 binding GO:0051430 9.26 CRH GNAS
4 11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity GO:0003845 8.96 HSD11B1 HSD11B2
5 hormone activity GO:0005179 8.92 CRH GH1 POMC SST

Sources for Cushing's Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....